Skip to main content
. 2017 Jul 28;8(47):82609–82620. doi: 10.18632/oncotarget.19664

Figure 2. BE(2)-C/LM2 demonstrates enhanced growth potential in vitro.

Figure 2

(A) BE(2)-C/LM2 cells have enhanced proliferative rates in our tetrazolium-based assay compared to parental control (BE(2)-C/Luc) starting at 48 h. (B) Enhanced anchorage-independent growth and (C) neurosphere formation was also demonstrated in the BE(2)-C/LM2 subclone (mean ± SEM; *= p< 0.05).